三大指数小幅上涨，两市半日成交额超1.6万亿。金田股份5连板，济民健康4连板，一图看懂>> 申联牛物 3天3板 公司开展并购重组布局人用 域或设立并购基余投资收账 聚焦公司核心技术平台，包 核酸（mRNA）以及合成多 具有协同效应的生物医药标 福瑞股份 2天2板 国内肝病诊治领域龙头企业 精性脂肪性肝炎）治疗重大 期大到主要临床终点 博济医药 公司主要为国内外制药企业 品、医疗器械的研发与生产 式" CRO服务，CRO服务f 康缘药业 公司被国家及各省新冠防治 括：散寒化湿颗粒、金振C 粒、热毒宁注射液、藿香正 济民健康 4天4板 公司子公司博鳌国际医院拥 日本国厚生省认证的国际更 了包括细胞存储、国际标准 临床研究、干细胞与再生医 技术平台，医院自体脂肪干 量检定 立方制药 3天2板 公司此前收到国家药监局下 料药上市申请批准通知书》 体成分，有消炎止痒作用, 臭虫叮咬红肿等各种皮肤瘦 新天药业 3天3板 公司拟收购汇伦医药85.12 是小分子化学药，致力于有 心脑血管、妇科、男科等穷 益佰制药 主要涵盖抗肿瘤类、心血管 域,其中中药注射剂艾迪沼 品，与复方斑酱胶囊适用于 诚意药业 公司预计中报净利润同比增 ...

Core Insights - In 2024, the company expects a decline in both revenue and net profit, with projected figures of 3.898 billion and 392 million respectively, representing year-on-year decreases of 19.86% and 15.58% [1] - The first quarter of 2024 continues to show pressure on performance, with revenue of 878 million, down 35.38% year-on-year, and net profit of 83.41 million, down 38.37% [1] - The decline in first-quarter revenue is primarily attributed to a decrease in sales of the core injection product, Heat Toxicity Ning Injection [1][2] Product Performance - The core injection products have historically driven high growth, with Heat Toxicity Ning Injection sales exceeding 1 billion in 2013, but experiencing significant fluctuations due to policy changes [2] - The 2023 National Medical Insurance Directory allowed for increased sales of Heat Toxicity Ning Injection, reaching 6.077 million units, but sales fell to 4.195 million units in 2024, with inventory levels increasing by 759.11% [2] - Ginkgo Biloba Diterpene Amine Injection has also contributed to revenue growth, but its price dropped significantly after negotiations, limiting its growth potential [3] - The company’s oral liquid product, Jin Zhen Oral Liquid, has shown inconsistent sales performance, with year-on-year changes of 74.81%, -22.67%, and 5.13% from 2022 to 2024 [3] Financial Overview - In the first quarter, the injection product category generated approximately 340 million in revenue, down 36.86% year-on-year [4] - The overall revenue for the company in the first quarter was 867.22 million, with a total revenue decline of 35.79% [7] - The company reported a significant decline in operating cash flow, down 59.9% to 77 million in the first quarter, raising concerns about balancing cash flow health with long-term investments [9] New Product Developments - The company has received approvals for several new traditional Chinese medicine products, but their contribution to overall revenue remains limited, with a 10.34% decline in revenue from granules and powders in 2024 [6] - The company has not disclosed sales figures for the "Scattering Cold and Dampness Granules," a product related to COVID-19 treatment, despite investor inquiries [8]